Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  01:46PM ET
42.51
Dollar change
+2.40
Percentage change
5.98
%
Today, 11:00 AMModerna posts a Q4 2025 beat with $678M revenue and a narrowed GAAP loss of $2.11/share, cuts 2025 operating expenses by about $2.2B (above targets), and reiterates its 2026 outlook for up to ~10% revenue growth despite a U.S. flu Refusal-to-File, with filings accepted in the EU, Canada and Australia; it also details 2026 guidance calling for a roughly 50/50 U.S.-international revenue split, about $0.9B cost of sales, $3.0B R&D, $1.0B SG&A, and year-end cash of $5.5–$6.0B.
IndexS&P 500 P/E- EPS (ttm)-8.06 Insider Own8.54% Shs Outstand391.00M Perf Week3.66%
Market Cap16.61B Forward P/E- EPS next Y-4.59 Insider Trans-0.07% Shs Float357.38M Perf Month4.76%
Enterprise Value12.84B PEG- EPS next Q-2.08 Inst Own73.19% Short Float20.01% Perf Quarter59.15%
Income-3.12B P/S7.44 EPS this Y8.93% Inst Trans-4.04% Short Ratio6.17 Perf Half Y59.27%
Sales2.23B P/B1.78 EPS next Y30.51% ROA-22.31% Short Interest71.51M Perf YTD44.15%
Book/sh23.86 P/C3.69 EPS next 5Y27.59% ROE-29.32% 52W High55.20 -22.99% Perf Year33.18%
Cash/sh11.53 P/FCF- EPS past 3/5Y- -42.94% ROIC-31.11% 52W Low22.28 90.80% Perf 3Y-75.21%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-43.99% 121.86% Gross Margin38.93% Volatility7.09% 7.61% Perf 5Y-76.86%
Dividend TTM- EV/Sales5.75 EPS Y/Y TTM-38.95% Oper. Margin-155.15% ATR (14)3.23 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.73 Sales Y/Y TTM-56.00% Profit Margin-139.61% RSI (14)54.65 Recom2.96
Dividend Gr. 3/5Y- - Current Ratio3.93 EPS Q/Q-1673.01% SMA20-3.54% Beta1.35 Target Price37.63
Payout- Debt/Eq0.08 Sales Q/Q-45.44% SMA5015.68% Rel Volume1.45 Prev Close40.11
Employees5800 LT Debt/Eq0.07 EarningsFeb 13 BMO SMA20044.82% Avg Volume11.59M Price42.51
IPODec 07, 2018 Option/ShortYes / Yes EPS/Sales Surpr.17.07% 6.75% Trades Volume11,284,334 Change5.98%
Date Action Analyst Rating Change Price Target Change
Jan-28-26Resumed Barclays Equal Weight $25
Jan-07-26Resumed UBS Neutral $34
Dec-12-25Initiated Jefferies Hold $30
Mar-13-25Initiated Citigroup Neutral $40
Feb-18-25Downgrade Barclays Overweight → Equal Weight $111 → $45
Jan-29-25Downgrade Goldman Buy → Neutral $99 → $51
Dec-18-24Downgrade Argus Buy → Hold
Dec-10-24Resumed BofA Securities Underperform $41
Nov-19-24Initiated Berenberg Hold $42
Nov-18-24Upgrade HSBC Securities Hold → Buy $58
Today 12:27PM
12:03PM
11:38AM
11:17AM
10:59AM
10:49AM Loading…
10:49AM
10:47AM
10:42AM
10:35AM
10:27AM
10:09AM
10:01AM
10:01AM
09:42AM
09:14AM
09:03AM Loading…
09:03AM
08:20AM
08:20AM
07:56AM
07:42AM
07:29AM
07:15AM
07:13AM
07:12AM
07:11AM
07:00AM
05:54AM
Feb-12-26 07:55PM
07:00PM
06:48PM
06:48PM Loading…
06:48PM
06:48PM
06:48PM
06:48PM
12:40PM
10:46AM
08:11AM
08:11AM
07:27AM
06:40AM
03:09AM
Feb-11-26 10:01PM
09:23PM
07:28PM
06:20PM
04:45PM
04:36PM
04:36PM
04:35PM
04:05PM
03:13PM
02:57PM
01:33PM
01:00PM
12:29PM
12:27PM
11:46AM
10:45AM
10:44AM
10:00AM
09:44AM
08:24AM
08:11AM
07:05AM
06:44AM
06:18AM
06:18AM
06:01AM
05:37AM
05:21AM
04:33AM
03:38AM
01:49AM
Feb-10-26 11:24PM
07:14PM
06:04PM
05:02PM
05:02PM
02:03PM
12:26PM
11:01AM
10:45AM
08:15AM
07:00AM
06:41AM
Feb-09-26 05:45PM
04:54PM
04:08PM
01:28PM
11:38AM
11:30AM
10:22AM
08:09AM
07:51AM
Feb-06-26 07:00PM
04:31PM
12:33PM
10:10AM
10:10AM
10:00AM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AFEYAN NOUBARDirectorDec 11 '25Option Exercise10.9023,853259,99827,777Dec 15 09:00 AM
AFEYAN NOUBARDirectorDec 11 '25Sale29.4823,853703,3063,924Dec 15 09:00 AM
Bancel StephaneChief Executive OfficerDec 11 '25Option Exercise10.90688,0737,499,9966,181,970Dec 15 08:59 AM
Flagship Pioneering Inc.AffiliateDec 11 '25Proposed Sale29.4923,853703,306Dec 11 04:30 PM
Hussain AbbasDirectorDec 09 '25Sale27.6050413,9101,515Dec 11 04:16 PM
Hussain AbbasDirectorDec 09 '25Proposed Sale27.6050413,910Dec 09 10:26 AM
Hussain AbbasDirectorJun 11 '25Sale28.003128,736580Jun 12 04:22 PM
Hussain AbbasDirectorJun 11 '25Proposed Sale28.003128,736Jun 11 10:06 AM
Bancel StephaneChief Executive OfficerMar 03 '25Buy31.22160,3145,004,3189,210,686Mar 04 04:27 PM
SAGAN PAULDirectorMar 03 '25Buy31.7631,6201,004,251312,027Mar 04 04:24 PM